TRENDING NEWS - COVID-19 VACCINE
|Dry run detailed steps shared by Dr Harsh Vardhan |
from his Twitter handle @drharshvardhan
The Covishield vaccine candidate has received the green signal from the Subject Expert Committee formed by the Drugs Controller General of India.
Made In India vaccine, Covishield is manufactured by the Serum Institute of India (SII) at their Pune facility. It is developed by pharmaceutical company AstraZeneca and the University of Oxford.
The DCGI heads the Central Drugs Standard Control Organization of the Government of India. It is responsible for regulatory control and approval of serum or sera, clinical trials, new drugs, specific licenses and control over import of drugs among other functions.
The CDSCO works under the guidance of the Ministry of Health and Family Welfare, currently led by Dr Harsh Vardhan.
The Subject Expert Committee, called the SEC has cleared the Covishield for emergency use, also known as Emergency Use Authorisation or Approval.
The SEC has sent its recommendation to the DCGI who, as the final authority, will help ensure the vaccine is available nationwide.
The vaccine will be made available initially to priority groups such as our nation's frontline medical professionals who continue to treat the Covid-19 virus afflicted citizens despite risk to their own lives.
"The preparations are like general elections. The purpose of the dry run is to be ready for the actual rollout... Potential recipients of vaccine will be informed via SMS. Frontline workers are the priority. After inoculation, digital certificate will also be provided," NDTV quoted health minister Harsh Vardhan saying.
POINTS YOU NEED TO KNOW
- India ranks as the country with the second-highest number of Covid-19 cases after the United States.
- The Government of India aims to vaccinate 30 crore people in six to eight months, starting January 2021.
- Serum Institute of India is the world's largest manufacturer of vaccines.
- SII plans to roll out about 100 million vaccine shots by March, 2021.
- Covishield is reported to be easier to transport and deliver at various centres in the country. It does not need extremely low temperatures for storage. It is also cheap and easy to mass-produce.
- Covishield's testing involves 1600 volunteers as part of its phase 2 and 3 trials.
- The Government of India plans to distribute the vaccines using the Covid Vaccine Intelligence Network (CoWIN) system. It's a digitalised platform that'll help roll out and scale up distribution of the vaccine.
- CoWIN will also help track beneficiaries on a real-time basis.